The result of Pfizer Inc.’s quest for a potential Lipitor OTC switch would reverberate across the industry as other firms likely would follow with proposals to switch ingredients for chronic conditions FDA wants to target with OTCs.
FDA’s interest in fostering innovation in OTC switches could work in favor of a 10mg Lipitor switch or a proposal...